RxDoctor Payments Data

Amber Woodfield, PA

Physician Assistant · Greenville, TXNPI 1104828433

Payments from drug & device makers

$1,910in general payments, 2019–2025

Across 74 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$188
  • Otsuka America Pharmaceutical, Inc.$186
  • GSK$157
  • Amgen$148
  • Lilly USA, LLC$136
  • Novo Nordisk$125
  • plus $971 from 25 others

What the payments were for

  • Food & beverage$1,910100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,910 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$56,353
Medicare patients
129
Services billed
981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$37,202
EliquisApixaban15$17,013
OzempicSemaglutide16$15,414
FarxigaDapagliflozin Propanediol11$9,279
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,559
Albuterol Sulfate HfaAlbuterol Sulfate76$2,112
Lansoprazole35$1,134
Levothyroxine Sodium113$969
Levetiracetam13$839
Gabapentin54$776
Omeprazole35$639
Acetaminophen-CodeineAcetaminophen With Codeine33$602
Atorvastatin Calcium109$597
Duloxetine Hcl22$584
Bupropion XlBupropion Hcl27$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$136$37,20235 claims
PfizerEliquis$100$17,01315 claims
Novo NordiskOzempic$125$15,41416 claims
AstraZenecaFarxiga$77$9,27911 claims
GSKTrelegy Ellipta$157$8,55913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Greenville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →